Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Viking Therapeutics, Inc. clinical trials
The registry lists 13 studies whose lead sponsor is Viking Therapeutics, Inc.. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 16, 2026.
Keep track of what changes. Save the Viking Therapeutics, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Viking Therapeutics, Inc..
- Viking Therapeutics, Inc.13 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 13 of 13.
- Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)Not yet recruitingNCT07868939Phase 3
- Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)Not yet recruitingNCT07868835Phase 3
- A Phase 1 Study of VK3019 in Overweight and Obese Adults Without ComorbiditiesRecruitingNCT07846033Phase 1
- A Phase 1 Study of VK2735 in Obese Adults Without ComorbiditiesRecruitingNCT07838740Phase 1
- VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)Active, not recruitingNCT07104383Phase 3
- Acute Hip Fracture Study in Patients 65 Years or GreaterCompletedNCT02578095Phase 2
- VK2735 for Weight Management Phase 3Active, not recruitingNCT07104500Phase 3
- VK2735 for Weight Management Phase 2 (Venture Oral Dosing)CompletedNCT06828055Phase 2
- A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMNCompletedNCT04973657Phase 1
- Phase 1 Study to Evaluate the Safety and Tolerability of VK2735CompletedNCT05203237Phase 1
- VK2735 for Weight Management Phase 2CompletedNCT06068946Phase 2
- A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASHCompletedNCT04173065Phase 2
- Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver DiseaseCompletedNCT02927184Phase 2